uniQure N.V. Earnings Recaps
Q3 2025
Nov 10, 2025
uniQure N.V. delivered strong top-line results from its pivotal Phase 1/2 study of AMT-130, marking a significant milestone in Huntington's disease treatment, although FDA feedback introduces uncertainty regarding the expected BLA submission timeline.
Key takeaways
- AMT-130 demonstrated a statistically significant 75% slowing of disease progression over three years, meeting pivotal study endpoints.
- The FDA's recent feedback has raised concerns over the adequacy of AMT-130's evidence for a BLA submission, leading to uncertainty regarding the submission timeline.
- In addition to Huntington's, uniQure is advancing AMT-260 for epilepsy, with active recruitment of clinical sites and initial positive data expected next year.
- Results from the Phase 1/2a trial of AMT-191 for Fabry disease show promising enzyme activity, with one patient successfully withdrawing from enzyme replacement therapy.
- uniQure remains committed to engaging with the FDA to expedite the path forward for AMT-130 despite the recent setbacks.
Q2 2025
Aug 2, 2025
uniQure's second quarter of 2025 demonstrated significant advances in its clinical pipeline, highlighted by regulatory progress and manufacturing readiness for AMT-130, positioning the company for a potentially transformative second half of the year.
Key takeaways
- Achieved breakthrough therapy designation for AMT-130 in Huntington's disease, marking a pivotal step in regulatory alignment.
- Completed manufacturing of two pre-PPQ GMP batches and advanced to the formal PPQ campaign, ensuring BLA readiness for early 2026 submission.
- Received alignment from the FDA on the statistical analysis plan, validating the use of an external control for the AMT-130 registrational endpoint.
- Early clinical data for AMT-260 shows a promising 92% reduction in seizure frequency for the first patient treated, generating interest in the epilepsy community.
- Continued preparation for a potential commercial launch in 2026, with key leadership appointments and strategic recruitment efforts underway.